Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unichem Becomes A Part Of Ipca As Its Holding Moves Above 50%

Acquisition Price Described As Expensive By Analysts, Cite Need For Turnaround

Executive Summary

Ipca Laboratories has completed an open offer for another slice of Unichem, following a recent deal to acquire a third of the company.

You may also be interested in...



Ipca Strikes Biosimilar Technology Transfer Amid Rising Ambitions In The Space

Ipca Laboratories underlined its commitment to successfully developing quality and affordable biosimilars meeting global standards as it penned a technology transfer agreement with a fellow Indian firm.

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel